论文部分内容阅读
目的 To explore the possible role of N3 PUFA in lowering inflammation markers in people diagnosed as T2DM and pre-diabetes方法 PubMed,CNKI and Cochrane Databases were searched before December 30th,2014.Randomized controlled trials,reference papers of studies or reviews were retrieved and screened according to the inclusion and exclusion criteria.Screening by two independent researchers,RCTs reporting the specific type,dose,frequency,duration of N3 PUFA and also the baseline and after-treatment level of inflammation markers including IL-2,IL-6,TNF-α,hcy and CRP were selected for final analysis.结果 7 RCTs were selected into final analysis including 526 participants with average mean age from 50 to 61.2y.Intervention duration ranges from 6w to 12w.EPA and DHA capsules were the most commonly used intervention.N3 PUFA,in the form of either EPA,DHA,ALA,was used with a minimum daily dose of 0.84g/d,and a maximum one was 6.6g/d.Only IL-2,TNF-α and hcy levels showed significantly reduction after treatment when compared with baseline in 2 studies.结论 The number of RCTs,sample size and quality of research are the obstacles to draw definite conclusion on the anti-inflammation effect of N3 PUFA.